Alpha Cognition Inc. (ACOG) announced preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury. The data provides additional evidence of the benefits of ALPHA-1062 in treating mTBI resulting from repetitive blast trauma, a highly relevant military injury.
Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families, as reported by Acme Health Corporation (AHC).
The stock had closed the regular session at $9.20, with a trading volume of 21.50 thousand shares. During the day, ACOG’s price fluctuated between $8.99 and $9.30, opening at $9.30 before closing higher in the extended hours
